echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The annual treatment cost is less than 20,000 yuan. The fifth domestic PD-1 pricing flows out

    The annual treatment cost is less than 20,000 yuan. The fifth domestic PD-1 pricing flows out

    • Last Update: 2021-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, the fifth domestically produced PD-1-Kangfang Biologics and CP Tianqing's Paimrizumab injection (Annico) is priced out: the retail price is 4875 yuan/100mg, combined with the supporting drug policy.


    Spend less than 20,000 a year

    Spend less than 20,000 a year

    On August 5 this year, Annikol was approved to be marketed for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma (r/r cHL) after at least second-line chemotherapy


    Anniker is a recombinant humanized anti-PD-1 monoclonal antibody independently developed by Kangfang Biology.


    According to the pricing plan and patient assistance plan that have flowed out recently:

    According to the pricing plan and patient assistance plan that have flowed out recently:

    The price per bottle of Anike is 4875 yuan/100mg (200mg each time, once every 2 weeks);

    According to the Beijing Kangmeng Charity Foundation, Anike’s patient assistance program is specifically: the first round of assistance program adopts the 2+1 model, that is, after the patient purchases and uses 2 cycles (4), 1 cycle (2) is given away.


    In terms of pricing, Anicol has the highest unit specifications compared to the 4 domestically-made PD-1s that have been on the market.


    Low price entry under fierce competition

    Low price entry under fierce competition

    It is reported that Chia Tai Tianqing, China Biopharmaceuticals, and Kangfang Biotechnology have jointly stated that Anike’s pricing and rescue plan is based on its more competitive and differentiated considerations in terms of efficacy and safety compared to the same period last year, taking into account the current PD- 1 The competition pattern of the monoclonal antibody market is also preparing for the entry of other major indications into medical insurance in 2022


    The current domestic PD-1 volume is serious.


    In addition, in terms of the indications approved by Annik, Hodgkin’s lymphoma is not a major disease, and BeiGene, Hengrui, and Xinda’s PD-1 have all been approved for this indication.


    Therefore, Annik's low price entry at this time is a strategy


    According to a report from the Health and Awareness Bureau, some people in the industry said that the average market price of PD-1 is about 50,000 yuan, which does not seem to be high, but public hospitals will consider the issue of medical insurance coverage


    In addition, with CP Tianqing’s advantages in channels, Annik’s future sales may not be bad


    summary

    summary

    The treatment cost of 39,000 yuan / 2 years has indeed refreshed people's impression of the price of PD-1


    To what extent can the annual cost of PD-1 be reduced? This year's medical insurance negotiations may reveal the answer


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.